Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metrological Protocols for Reaching Reliable and SI-Traceable Size Results for Multi-Modal and Complexly Shaped Reference Nanoparticles.
Feltin N, Crouzier L, Delvallée A, Pellegrino F, Maurino V, Bartczak D, Goenaga-Infante H, Taché O, Marguet S, Testard F, Artous S, Saint-Antonin F, Salzmann C, Deumer J, Gollwitzer C, Koops R, Sebaïhi N, Fontanges R, Neuwirth M, Bergmann D, Hüser D, Klein T, Hodoroaba VD. Feltin N, et al. Among authors: koops r. Nanomaterials (Basel). 2023 Mar 9;13(6):993. doi: 10.3390/nano13060993. Nanomaterials (Basel). 2023. PMID: 36985886 Free PMC article.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Selectivity Map for Molecular Beam Epitaxy of Advanced III-V Quantum Nanowire Networks.
Aseev P, Fursina A, Boekhout F, Krizek F, Sestoft JE, Borsoi F, Heedt S, Wang G, Binci L, Martí-Sánchez S, Swoboda T, Koops R, Uccelli E, Arbiol J, Krogstrup P, Kouwenhoven LP, Caroff P. Aseev P, et al. Among authors: koops r. Nano Lett. 2019 Jan 9;19(1):218-227. doi: 10.1021/acs.nanolett.8b03733. Epub 2018 Dec 19. Nano Lett. 2019. PMID: 30521341 Free PMC article.
13 results